Issue Date: March 6, 2017
Astellas, Affinivax form vaccine pact
Astellas Pharma and Affinivax are joining to develop a vaccine targeting Streptococcus pneumoniae, a bacterium that kills more than 1.6 million people per year, according to the World Health Organization. The partners will use Affinivax’s multiple antigen-presenting system technology, said to enable the binding of protective polysaccharides and proteins in a single vaccine. Japan-based Astellas will pay Affinivax $10 million up front as well as potential milestone payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society